Response of blood pressure after percutaneous transluminal renal artery angioplasty and stenting

Table 3 Levels of sIL-2R, alanine aminotransferase, and hepatitis B virus DNA in the sera of patients with chronic HBV infection (mean ± SD)

Group1	n	mean ± SD	P value
Age (yr)			0.51
A	26	56.81 ± 13.87
B	49	54.80 ± 11.55
Initial systolic BP (mmHg)			0.01
A	26	179.31 ± 20.32
B	49	166.00 ± 18.76
Initial diastolic BP (mmHg)			0.04
A	26	101.92 ± 10.90
B	49	96.79 ± 10.14
Initial mean BP (mmHg)			0.01
A	26	141.00 ± 17.73
B	49	129.00 ± 16.76
No. of medications			0.01
A	26	3.26 ± 0.77
B	49	2.87 ± 0.57
Creatinine (mg/dL)			0.07
A	26	1.38 ± 0.48
B	49	1.11 ± 0.66
Diameter of stent			0.23
A	26	5.76 ± 0.94
B	49	6.05 ± 0.98
Percent of renal artery stenosis (RAS)			0.05
A	26	87.65 ± 7.71
B	49	83.79 ± 8.40
GFR (mL/min)			0.01
A	26	54.03 ± 24.22
B	49	72.97 ± 25.43
Duration of HT (yr)			0.55
A	26	4.00 ± 3.96
B	49	3.40 ± 3.32

Values are presented as mean ± SD.

¹Group A: Patients who did not show blood pressure reduction after percutaneous transluminal renal artery (PTRA) (26 patients); group B: Patients who showed blood pressure reduction after PTRA (49 patients). HT: Hormone Therapy; BP: Blood pressure; GFR: Glomerular filtration rate.